Building the future of neurogenetic disease treatments
Building the future of neurogenetic disease treatments
Gene therapies engineered for the central nervous system and built around patients.
Explore Our Science
WHO WE ARE
Genesis Gene Therapies is led by experienced scientists, clinicians, and biotech professionals dedicated to translating breakthrough science into therapies for patients with urgent unmet medical needs.
Our scientific foundation is built upon innovations pioneered by Professors Steven Gray PhD., Berge Minassian MD., and Ryan Butler PhD., at UTSouthwestern Medical Center, whose gene therapy programs have contributed to the advancement of more than 10 AAV-based gene therapies into clinical development across multiple neurological and rare genetic diseases.

Souad Messahel, PhD, CEO & Founding Partner
Dr. Souad Messahel is a translational neuroscientist with more than 25 years of experience in clinical research. Her work focuses on advancing rare disease drug development programs from preclinical through global clinical development. She has led multidisciplinary teams across clinical operations, and regulatory strategy in the U.S. and Europe.
Souad drives portfolio strategy and execution, building scalable development frameworks that accelerate innovative therapies for patients with rare neurogenetic diseases. Her expertise lies in bridging scientific innovation with operational excellence to deliver meaningful patient impact.

Berge Minassain, MD, Founding Partner
Dr. Berge Minassian is a physician-scientist and internationally recognized expert in pediatric neurology and rare neurogenetic disorders. With decades of experience in translational research and clinical development, his work has focused on advancing novel therapies for severe neurological diseases, including epilepsy and other rare genetic conditions. He has led groundbreaking research in Lafora disease and other glycogen storage diseases that have expanded the understanding of disease mechanisms and accelerated the development of innovative treatment approaches.

Steven Gray, PhD, Founding Partner
Dr. Steven Gray is a leading gene therapy scientist and internationally recognized expert in adeno-associated virus (AAV) vector engineering and CNS-directed gene therapy. His work has focused on developing novel AAV vectors and translating gene therapies for severe neurological and neurogenetic disorders from the laboratory into human clinical trials. His research has contributed to gene therapy programs spanning Rett syndrome, giant axonal neuropathy, Tay-Sachs and Sandhoff diseases, SPG50, and multiple forms of Batten disease.

Ryan Butler, PhD, Founding Partner
Dr. Ryan Butler is a neuroscientist and gene therapy researcher specializing in the development of genetic therapies for neurodegenerative and neurodevelopmental disorders. His work includes the development of gene therapy approaches for Angelman syndrome, Prader-Willi syndrome, Friedreich’s ataxia, and other rare monogenetic and complex genetic disorders. He is also an active education leader for medical, graduate and undergraduate students as well as an outreach spokesman to foundations on the topics of gene therapy and rare diseases.

Souad Messahel, PhD
CEO & Founding Partner
Souad Messahel, PhD
CEO & Founding Partner
Dr. Souad Messahel is a translational neuroscientist with more than 25 years of experience in clinical research. Her work focuses on advancing rare disease drug development programs from preclinical through global clinical development. She has led multidisciplinary teams across clinical operations, and regulatory strategy in the U.S. and Europe. Souad drives portfolio strategy and execution, building scalable development frameworks that accelerate innovative therapies for patients with rare neurogenetic diseases. Her expertise lies in bridging scientific innovation with operational excellence to deliver meaningful patient impact.

Berge Minassian, MD
Founding Partner
Berge Minassian, MD
Founding Partner
Dr. Berge Minassian is a physician-scientist and internationally recognized expert in pediatric neurology and rare neurogenetic disorders. With decades of experience in translational research and clinical development, his work has focused on advancing novel therapies for severe neurological diseases, including epilepsy and other rare genetic conditions. He has led groundbreaking research in Lafora disease and other glycogen storage diseases that have expanded the understanding of disease mechanisms and accelerated the development of innovative treatment approaches.

Berge Minassian, MD
Founding Partner
Berge Minassian, MD
Founding Partner
Dr. Berge Minassian is a physician-scientist and internationally recognized expert in pediatric neurology and rare neurogenetic disorders. With decades of experience in translational research and clinical development, his work has focused on advancing novel therapies for severe neurological diseases, including epilepsy and other rare genetic conditions. He has led groundbreaking research in Lafora disease and other glycogen storage diseases that have expanded the understanding of disease mechanisms and accelerated the development of innovative treatment approaches.

Steven Gray, PhD
Founding Partner
Steven Gray, PhD
Founding Partner
Dr. Steven Gray is a leading gene therapy scientist and internationally recognized expert in adeno-associated virus (AAV) vector engineering and CNS-directed gene therapy. His work has focused on developing novel AAV vectors and translating gene therapies for severe neurological and neurogenetic disorders from the laboratory into human clinical trials. His research has contributed to gene therapy programs spanning Rett syndrome, giant axonal neuropathy, Tay-Sachs and Sandhoff diseases, SPG50, and multiple forms of Batten disease.

Steven Gray, PhD
Founding Partner
Steven Gray, PhD
Founding Partner
Dr. Steven Gray is a leading gene therapy scientist and internationally recognized expert in adeno-associated virus (AAV) vector engineering and CNS-directed gene therapy. His work has focused on developing novel AAV vectors and translating gene therapies for severe neurological and neurogenetic disorders from the laboratory into human clinical trials. His research has contributed to gene therapy programs spanning Rett syndrome, giant axonal neuropathy, Tay-Sachs and Sandhoff diseases, SPG50, and multiple forms of Batten disease.

Ryan Butler, PhD
Founding Partner
Ryan Butler, PhD
Founding Partner
Dr. Ryan Butler is a neuroscientist and gene therapy researcher specializing in the development of genetic therapies for neurodegenerative and neurodevelopmental disorders. His work includes the development of gene therapy approaches for Angelman syndrome, Prader-Willi syndrome, Friedreich’s ataxia, and other rare monogenetic and complex genetic disorders. He is also an active education leader for medical, graduate and undergraduate students as well as an outreach spokesman to foundations on the topics of gene therapy and rare diseases.

Ryan Butler, PhD
Founding Partner
Ryan Butler, PhD
Founding Partner
Dr. Ryan Butler is a neuroscientist and gene therapy researcher specializing in the development of genetic therapies for neurodegenerative and neurodevelopmental disorders. His work includes the development of gene therapy approaches for Angelman syndrome, Prader-Willi syndrome, Friedreich’s ataxia, and other rare monogenetic and complex genetic disorders. He is also an active education leader for medical, graduate and undergraduate students as well as an outreach spokesman to foundations on the topics of gene therapy and rare diseases.
THE CHALLENGE
The CNS demands more from gene therapy.
AAV medicines hold enormous potential. Reaching neurons across the brain and spinal cord remains the challenge.
01 Enhance blood-brain barrier penetration
02 Improve neuronal transduction
03 Increase therapeutic gene expression
04 Enable delivery throughout brain and spinal cord
